**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 39323**

**Manuscript Type: MINIREVIEWS**

**Treatment of *Helicobacter pylori* infection in atrophic gastritis**

Lahner E *et al*. *H. pylori* treatment in atrophic gastritis

Edith Lahner, Marilia Carabotti, Bruno Annibale

**Edith Lahner, Marilia Carabotti, Bruno Annibale,** Medical-Surgical Department of Clinical Sciences and Translational Medicine, Sant’Andrea Hospital, University Sapienza, Rome 00189, Italy

**ORCID number:** Edith Lahner (0000-0002-9503-8639); Marilia Carabotti (0000-0001-9984-4630); Bruno Annibale (0000-0001-9120-5957).

**Author contributions:** Lahner E designed the review and wrote the paper; Carabotti M performed the literature search and revised the paper; Annibale B supervised and approved the final version of the review.

**Conflict-of-interest statement:** The authors declare no potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Bruno Annibale, MD, PhD,** **Full Professor,** Medical-Surgical Department of Clinical Sciences and Translational Medicine, Sapienza University of Rome, Via Grottarossa 1035, Rome 00189, Italy. [bruno.annibale@uniroma1.it](mailto:bruno.annibale@uniroma1.it)

**Telephone:** +39-6-33775289

**Fax:** +39-6-33776006

**Received:** April 12, 2018

**Peer-review started:** April 13, 2018

**First decision:** April 27, 2018

**Revised:** May 16, 2018

**Accepted:** May 26, 2018

**Article in press:**

**Published online:**

**Abstract**

*Helicobacter pylori (H. pylori)* is a major human pathogen causing chronic, progressive gastric mucosal damage and is linked to gastric atrophy and cancer. *H. pylori*-positive individuals constitute the major reservoir for transmission of infection. There is no ideal treatment for *H. pylori*. *H. pylori* infection is not cured by a single antibiotic, and sometimes, a combined treatment with three or more antibiotics is ineffective. Atrophic gastritis (AG) is a chronic disease whose main features are atrophy and/or intestinal metaplasia of the gastric glands, which arise from long-standing *H. pylori* infection. AG is reportedly linked to an increased risk for gastric cancer, particularly when extensive intestinal metaplasia is present. Active or past *H. pylori* infection may be detected by conventional methods in about two-thirds of AG patients. By immunoblotting of sera against *H. pylori* whole-cell protein lysates, a previous exposure to *H. pylori* infection is detected in all AG patients. According to guidelines, AG patients with *H. pylori* positivity should receive eradication treatment. The goals of treatment are as follows: (1) Cure of infection, resolution of inflammation and normalization of gastric functions; (2) possible reversal of atrophic and metaplastic changes of the gastric mucosa; and (3) prevention of gastric cancer. An ideal antibiotic regimen for *H. pylori* should achieve eradication rates of approximately 90%, and complex multidrug regimens are required to reach this goal. Amongst the factors associated with treatment failure are high bacterial load, high gastric acidity, *H. pylori* strain, smoking, low compliance, overweight, and increasing antibiotic resistance. AG, when involving the corporal mucosa, is linked to reduced gastric acid secretion. At a non-acidic intra-gastric pH, the efficacy of the common treatment regimens combining proton pump inhibitors with one or more antibiotics may not be the same as that observed in patients with *H. pylori* gastritis in an acid-producing stomach. Although the efficacy of these therapeutic regimens has been thoroughly tested in subjects with *H. pylori* infection, there is a paucity of evidence in the subgroup of patients with AG. Bismuth-based therapy may be an attractive treatment in the specific setting of AG, and specific studies on the efficacy of bismuth-based therapies are needed in patients with AG.

**Key words:** Atrophic gastritis; Intestinal metaplasia; *Helicobacter pylori*; Eradication treatment; Preneoplastic condition

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**:Atrophic gastritis (AG) may arise from long-standing *Helicobacter pylori* (*H. pylori*) infection and is linked to increased gastric cancer risk. According to guidelines, *H. pylori*-positive AG patients should receive eradication treatment. The goals of treatment are as follows: (1) Cure of infection, (2) possible reversal of atrophic/metaplastic changes, and (3) prevention of gastric cancer. When involving the corporal mucosa, AG is linked to reduced acid secretion. At a non-acidic intra-gastric pH, the efficacy of common treatment regimens may not be the same as those observed in an acid-producing stomach. There is a paucity of evidence of efficacy of eradication regimens in AG patients. Bismuth-based therapies may be promising.

Lahner E, Carabotti M, Annibale B. Treatment of *Helicobacter pylori* infection in atrophic gastritis. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*), a gram-negative bacterium inhabiting the luminal surface of the gastric epithelium first isolated in 1982, is thought to have infected humans for more than 50000 years. *H. pylori* is the most infectious human pathogen, affecting approximately 50% of the population. In Northern Europe and North America, about one-third of adults have this bacterium, whereas in Southern and Eastern Europe, South America, and Asia, more than half of people are estimated to be infected. *H. pylori* infection occurs commonly in developing countries, whereas the infection rates are decreasing in developed countries, potentially indicating that socioeconomic status and living standards might play roles in the distribution of the infection[1].

As elegantly summarized by De Francesco et al., there is still no ideal treatment against *H. pylori*, and the “therapeutic battle” continues, probably for several reasons; *H. pylori* is a peculiar bacterium characterized by some particular features: (1) This organism, notwithstanding its pathogenic nature, has been present in the stomach of humans for many thousands years; (2) it is one of the very few bacteria able to survive in acidic gastric juice, as it has developed its ecological niche between the mucus and the epithelial layer; (3) its chronic presence in the human stomach may lead to benign and malignant disorders in the upper gastrointestinal tract and even to some disorders outside of the gastrointestinal tract; (4) although gram-negative, *H. pylori* is sensitive to penicillin, which generally works better on the wall of gram-positive bacteria; (5) *H. pylori* infection is not cured by a single antibiotic, and sometimes, a combined treatment with three or more antibiotics is ineffective; and (6) since *H. pylori* is able to evade several immune defence mechanisms, no effective vaccine has been developed[2].

Atrophic gastritis (AG) is a chronic disease whose main features are atrophy and/or intestinal metaplasia of the gastric glands. When the oxyntic mucosa is involved, atrophy leads to a lack of both gastric acid and intrinsic factor production as well as to cobalamin or iron malabsorption and eventually anaemia[3,4]. AG is a complex condition that may arise from long-standing *H. pylori* infection or in the context of autoimmune gastritis[5], and it is reportedly linked to an increased risk for gastric neoplasias such as intestinal-type adenocarcinoma and type 1 gastric carcinoids, in particular when extensive intestinal metaplasia is present[6]. In a meta-analysis, the ratios of the AG incidence in *H. pylori*-positive patients to that in *H. pylori*-negative ones ranged from 2.4 to 7.6, with a summary estimate of 5 (95%CI: 3.1-8.3)[7], thus suggesting a strong relationship between incidence of AG and *H. pylori* infection.

Ongoing *H. pylori* infection has been linked to an increased risk of gastric cancer, though the data are conflicting on whether the treatment of *H. pylori* infection prevents gastric cancer. *H. pylori* infection has also been identified as a decisive pathogenetic factor of gastric MALT lymphoma, and *H. pylori* eradication is the treatment of choice in all MALT lymphoma patients infected by the bacterium[1,8]. *H. pylori* has been classified as a class I carcinogen by the World Health Organization and the International Agency for Research on Cancer Consensus Group in 1994[8]. The Uemura study on 1526 Japanese subjects showed that gastric cancer developed in 2.9% of 1246 *H. pylori*-infected patients over 7.8 years, whereas gastric cancer was not observed in 280 uninfected control subjects or in a subgroup of 253 individuals who received *H. pylori* eradication therapy early during follow-up[9]. The greatest benefit of cure of *H. pylori* infection on gastric cancer risk in asymptomatic adults has been reported in regions with the highest incidence of gastric cancer; reported relative risks for regions of low, intermediate and high incidence of gastric cancer were 0.80, 0.49, and 0.45, respectively[10]. A recent study of nearly 39000 asymptomatic subjects showed that the cumulative incidence of gastric cancer was significantly higher in the non-eradication group (hazard ratio 4.1) compared to the eradication group or to the *H. pylori*-negative group[11], thus supporting the positive effect of *H. pylori* eradication on the prevention of gastric cancer in this setting.

A meta-analysis found that antral and body gastric atrophy could regress after eradicating *H. pylori* (pooled OR 0.5 and 0.2, *P* < 0.01), but this effect was not observed for intestinal metaplasia[12], suggesting that cure of *H. pylori* infection may have a beneficial long-term effect on gastric atrophy. Another meta-analysis reported that eradication of *H. pylori* is effective only in a subset of patients in whom intestinal metaplasia or dysplasia are absent[13]. Nevertheless, the reported predictors for body atrophy reversal were an absence of intestinal metaplasia (HR 2.4, 95%CI 1.2-4.8), mild atrophy (HR 2.14, 95%CI 1.12-4.1), and moderate-severe inflammation before treatment (HR 5.3; 95%CI 1.64-17.3)[14].

Given the important link between AG and gastric cancer, between gastric cancer and *H. pylori* infection, and between *H. pylori* infection and AG, the treatment of *H. pylori* infection in patients with AG is an important issue that we wish to focus on in this review.

**THE LINK BETWEEN AG AND GASTRIC CANCER**

AG, especially when associated with intestinal metaplasia, is a linked to a higher risk for gastric cancer, thus representing a precancerous condition. The eventual development of the intestinal-type gastric adenocarcinoma is the end result of an inflammation–metaplasia-dysplasia-carcinoma sequence, the so-called Correa cascade[15]. One important determinant of gastric cancer risk is how the precancerous changes in the gastric mucosa are distributed within the stomach. The oxyntic gland atrophy and/or the intestinal metaplasia distributed in a multifocal pattern, including the lesser curvature of the corpus and fundus (multifocal atrophic gastritis), reported as the “extensive” phenotype and has been associated with a higher risk of gastric cancer. The idea of ‘gastritis of the carcinoma phenotype’ proposes that corpus-predominant gastritis increases the risk of gastric cancer[16], probably due to changes in the intra-gastric milieu, such as increased pH, reduced ascorbic acid and the scavenging of nitrites, perhaps due to dysbiosis of the gastric microbiota[17,18] and probably also due to bacteria other than *H. pylori*, such as *Lachnospiraceae*, *Lactobacillaceae*, and *Streptococcaceae*[19].

Notwithstanding a growing body of evidence, the composition of a healthy gastric microbiota remains undefined, and the relationship between *H. pylori* and other gastric bacteria or other microorganisms is yet to be clarified. Some evidence shows that *H. pylor* decreases the diversity of the gastric microbiota, suggesting its predominance over other microorganisms. Therefore, *H. pylori* may represent the main but not the sole microbial trigger of gastric diseases, and microbes other than *H. pylori* may play a role in the occurrence of long-term complications of *H. pylori* infection[20]. Therefore, it might be speculated that the antibiotic treatment given for eradicating *H. pylori* may in some cases be beneficial for gastric cancer risk because it is efficacious in eliminating bacteria other than *H. pylori*.

Previous work tried to quantify the risk of gastric neoplasms in AG patients. A progression rate of AG to gastric cancer up to 2% yearly has been observed at follow-up periods up to 16 years[21,22]. A systematic review showed, in AG patients with pernicious anaemia, an estimated 7-fold relative risk of gastric cancer[23]. A very recent systematic review reported widely ranging annual incidence rates of gastric cancer in patients with gastric atrophy (0.53 to 15.24 per 1000 person years) and intestinal metaplasia (0.38 to 17.08 per 1000 person years)[24]. The clinical relevance of AG is supported by European guidelines recommending endoscopic-histologic surveillance with 3-year intervals in patients with moderate to severe extensive AG[25]. Similarly, the Kyoto guidelines on the management of *H. pylori* gastritis recommend surveillance of these patients[26].

**THE LINK BETWEEN *H. pylori* INFECTION AND AG**

AG is viewed as the first important step in the pathogenesis of gastric cancer, which probably develops in a multistep process beginning from chronic gastritis and going forward through AG, intestinal metaplasia, and dysplasia[15]. It is accepted that this sequence is usually triggered by *H. pylori* infection and is synergistically influenced by a variety of genetic and environmental factors. Amongst *H. pylori*-positive patients, only up to 2% of subjects will develop gastric cancer, supporting the idea that the final effects of *H. pylori* infection could be affected by its prevalence as well as environmental, bacterial, and host factors[8,27].

Amongst a prospective cohort of patients with AG involving the corporal mucosa, 22.6% and 52.7% of patients were *H. pylori*-positive as diagnosed, respectively, by histology of gastric biopsies and by anti-*H. pylori* IgG antibodies assessed by ELISA serology[28]. This result implied that there was active or past *H. pylori* infection in about two-thirds of these patients. A further study, investigating AG patients for previous exposure to *H. pylori* infection by immunoblotting of sera against *H. pylori* whole-cell protein lysates, observed that all the AG patients classified as *H. pylori*-negative by histology and conventional ELISA serology showed an immunoblotting seroreactivity, including in each case either cagA or vacA[29]; the concomitant seroreactivity against cagA and vacA was highly prevalent in the *H. pylori*-negative AG patients, similar to those with positive histologic infection (77.4% *vs* 86.2%) and with positive ELISA serology (*vs* 61.5%). These data suggest that immunoblotting is able to prove a previous exposure to *H. pylori* infection in virtually all patients with AG, making plausible a hidden role of the infection in this condition. In clinical practice, the presence of *H. pylori* infection in AG patients may be difficult to show, as non-invasive tests such as the urea breath test or the stool antigen test may be falsely negative, and the most reliable test seems to be the presence of active infection (acute inflammatory infiltration) on histological evaluation of gastric biopsies combined with *H. pylori* IgG serology[30].

As mentioned above, the outcome of *H. pylori* infection is highly strain- and host-dependent, which implies that multiple interplaying factors should be taken into consideration[31]. Amongst strain-dependent factors, a very recent systematic review showed that *H. pylori* strains positive for the virulence factors vacA, s1m1, and cagA can significantly increase the risk of gastric cancer, and these bacterial genetic markers may be used for risk stratification between different populations[32].

Corpus-predominant AG is considered one of the outcomes of *H. pylori* infection that puts patients at higher risk for gastric cancer[9]. A previous study using immunoproteome technology to identify *H. pylori* antigens showed that sera from AG (40.5% ± 2%) and gastric cancer patients (25.9% ± 1.8%) showed a significantly higher and stronger mean immunoreactivity *vs* *H. pylori* antigens compared to peptic ulcer patients (11.2% ± 1.3%). That method differentially recognized 17 *H. pylori* antigens[33]. These data suggest that patients with gastric cancer and those with AG, its precursor condition, may display a common serological immunorecognition pattern of *H. pylori* antigens, confirming the link between the infection and these conditions.

**TREATMENT OF *H. pylori* INFECTION IN AG**

*H. pylori* is a major human pathogen causing chronic and progressive gastric mucosal damage, and it is aetiologically related to gastric atrophy and gastric cancer. *H. pylori*-positive individuals constitute the major reservoir for transmission of the infection[8,34]. According to main guidelines and consensus statements[26,35,36], all *H. pylori*-positive individuals should receive eradication treatment unless competing considerations are present. This recommendation implies that all patients with AG and positivity to *H. pylori* should receive eradication treatment. The possible goals of treatment of *H. pylori* infection in AG patients are as follows: (1) Cure of infection, resolution of related mucosal inflammation and normalization of gastric functions (acid secretion); (2) possible reversal of atrophic and metaplastic changes of the gastric mucosa and preventing the lesions reaching the so-called point of no return, beyond which the reversibility of histological changes is virtually considered not possible anymore; and (3) finally, prevention or risk reduction of gastric cancer, as current evidence is consistent with the notion that cure of *H. pylori* infection may stop the progression of damage and may reduce the *H. pylori*-related events increasing genetic instability in the gastric mucosa[10,37,38].

The potential benefits of cure of *H. pylori* infection for a single individual, including in terms of cancer risk reduction, depend on the degree and extent of atrophic damage that has already occurred at the time of eradication and the eventual reversibility of that damage[26,35]. Amongst the several approaches to stratify the risk, the validated histological staging systems, such as operative link for gastritis assessment (OLGA) and operative link for gastric intestinal metaplasia assessment (OLGIM), may be mentioned[39,40]. In geographical areas with a sufficiently high expertise, endoscopic scoring systems such as that of Kimura and Takemoto can be applied, but histological confirmation is still recommended[41].

The reversibility of AG after *H. pylori* eradication remains a controversial issue. A recent meta-analysis of 12 studies reported that eradication was linked with a significant reduction in AG in the corpus (*P* = 0.006) but not in the antrum (*P* = 0.06); furthermore, there was evidence for a significant effect on intestinal metaplasia neither in the corpus (*P* = 0.42) nor in the antrum (*P* = 0.76)[42]. Two other meta-analyses observed consistent findings[12,13], showing significant improvement of gastric atrophy after cure of *H. pylori* infection, whereas improvement was not shown for intestinal metaplasia. A very recent long-term follow-up study reported that AG and intestinal metaplasia in the antrum and corpus improved only in the *H. pylori*-cured patients compared to baseline[43]. These data support the idea that *H. pylori* eradication may be a prevention strategy for gastric cancer through resolution/improvement of precancerous lesions.

**PROPOSED ERADICATION REGIMENS**

Since the 1990s, in different countries, national and international guidelines for the management of patients with *H. pylori* infection have been published. These guidelines generally comprise first-line therapy recommendations, which vary by country or region[26,35,44-51].

An ideal antibiotic regimen for *H. pylori* should achieve eradication rates of approximately 90%, and complex multidrug regimens are required to reach this goal. Amongst factors associated with treatment failure are high bacterial load, high gastric acidity, *H. pylori* strain, smoking, and low compliance. However, the increasing antibiotic resistance, particularly against clarithromycin, seems to be played a major role in poor outcomes. To limit the problem of resistance, a combination of drugs with no significant resistance would be necessary[2,35,44]. Decreasing eradication rates with standard therapies have prompted recent changes in recommended first-line therapies. Proposed treatment regimens are mainly bismuth-based triple therapies in Eastern guidelines, mainly concomitant and bismuth-based therapy in Western guidelines, and less commonly sequential or hybrid regimens[2]. However, these recommendations refer to chronic *H. pylori* gastritis, without taking into consideration the peculiar condition of AG.

In particular, AG, when involving the corporal mucosa, is notably linked to reduced gastric acid secretion and consequent hypochlorhydria. In this particular intra-gastric microenvironment with a non-acidic intra-gastric pH, the efficacy of the common treatment regimens using the combination of a proton pump inhibitor with one or more antibiotics may not be the same as observed in patients with *H. pylori* gastritis in an acid-producing stomach. Though the efficacy of these therapeutic regimens has been largely tested in subjects with *H. pylori* infection[52-54], there is a paucity of evidence in the subgroup of patients with AG. From some studies, albeit not designed for this aim, eradication rates of AG patients can be extrapolated, and they have ranged between 71% and 86%. In a previous study in which 192 patients with *H. pylori*-positive AG were treated with bismuth-based triple regimens, an overall eradication rate of 70.8% was achieved[14]. In another study, of 57 patients with intestinal metaplasia receiving standard triple therapy, the infection was successfully cured in 49 patients (eradication rate 85.9%)[55]. Less recent Japanese studies achieved eradication rates of 82.2% and 70.5%[56,57]. Table 1 summarizes the eradication rates reported in previous studies.

Bismuth-based therapy may be an attractive treatment in the specific setting of AG. Bismuth has been used for centuries in medicine. From a gastroenterological perspective, bismuth salts have been used to treat peptic ulcer disease, dyspepsia, parasitic infections, microscopic colitis, and infectious diarrhoea[58]. Soon after the discovery of *H. pylori*, Marshall highlighted that some antimicrobial compounds (*e.g.*, bismuth salts and metronidazole) had been used to treat peptic ulcer disease in the past with some success. These results led to a renewed interest in bismuth compounds, largely because bismuth was found to inhibit the growth of *H. pylori* and effective in eradicating the bacterium[59]. In 1995, two articles, independently and at the same time, showed that adding PPI to bismuth-based triple therapy increased treatment efficacy[60,61]. This combination mainly remained a rescue therapy during the following ten years, when the PPI-clarithromycin-based triple therapy was the standard therapy[62]. Bismuth has an established history in the treatment of *H. pylori*. Colloidal bismuth subcitrate has potent anti-*H. pylori* activity (MIC 4-32 μg/mL), and *in vitro* resistance has not been detected. Further, bismuth increases eradication when included in double, triple, and quadruple regimens[2].

In AG patients, in whom acid secretion is generally impaired, treatment with PPI may not make sense at all. Therefore, in this specific setting, bismuth-based therapy may represent a more promising treatment option, especially in the recent galenic formulation, bismuth subcitrate potassium, metronidazole, and tetracycline (BMT, sold under licence as Pylera®). In particular, this formula consists of 140 mg of bismuth subcitrate potassium (equivalent to Bi2O3), 125 mg of metronidazole and 125 mg of tetracycline hydrochloride given as a three-in-one capsule four times daily for ten days[63]. Generally, this formula is associated with 20 mg of omeprazole twice daily, which in hypochlorhydric AG patients is not indicated or even useless. One advantage of this three-in-one treatment is that it should allow us to standardize the doses of molecular antimicrobials, which is not always possible when the compounds are taken separately. Undeniably, 14 d triple therapy with bismuth salts, tetracycline and metronidazole was the first therapy to achieve consistently high *H. pylori* eradication rates[2,63]. The bismuth-based quadruple therapy is included among the recommended first-line therapies in the current European, United States, Canadian and Chinese guidelines[35,36,48,49]. Several studies have investigated the efficacy of bismuth-containing quadruple therapy. A previous systematic review showed that the triple capsule Pylera® achieved eradication rates ranging between 84% and 97%. Eradication rates were similar for clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable between metronidazole-resistant and -sensitive strains. This effect was not seen with the use of triple therapy in cases of clarithromycin resistance. Previous clinical trials did not report any serious side effects from bismuth-based regimens, and compliance was similar to standard triple therapy[63].

The safety of bismuth administration for *H. pylori* eradication has been confirmed in a systematic review of 35 randomized clinical trials with a total of 4763 patients, 2435 of whom were treated with bismuth salts[64]: no serious adverse event was reported with the bismuth therapy. There was also no statistically significant difference in the total number of adverse events between those receiving bismuth salts and other regimens or in the individual adverse events, that is, abdominal pain, diarrhoea, dizziness, headache, metallic taste, nausea or vomiting. A very recent Italian study compared 10 d sequential and bismuth-based quadruple therapies for first-line *H. pylori* treatment in 495 patients, achieving similarly high eradication rates (92% *vs* 91%) as first-line treatments for *H. pylori* infection in clinical practice[65]. Unfortunately, patients were not stratified according to pattern of gastritis.

Though bismuth salts represent a promising treatment in the setting of AG with a rationale based on the specific pharmacological, bacteriostatic properties of bismuth salts, the data on the efficacy and safety of bismuth-based regimens without use of PPIs in this specific setting are lacking and are urgently needed.

It should be kept in mind that patients with AG have a higher risk for gastric neoplasms and need endoscopic surveillance based on the extent and degree of these pre-neoplastic mucosal alterations as staged by OLGA/OLGIM. This outcome may have a negative impact on the quality of life of these patients. A recent paper showed that the quality of life (SF-8) scores on both the mental component summary and the physical component summary significantly improved after the eradication of *H. pylori*, irrespective of the symptoms, especially in patients who had an impaired quality of life before the eradication[66]. This improvement may represent a further reason to search for and to treat *H. pylori* infection in the specific setting of patients with AG, in whom the timely cure of *H. pylori* infection may lead to reversal of pre-neoplastic changes, restoration of gastric function, and elimination or reduction of gastric cancer risk, as schematically illustrated in Figure 1.

**CONCLUSION**

In the particular setting of AG, which is generally associated with a non-acidic intragastric pH, the efficacy of the common treatment regimens using proton pump inhibitors with one or more antibiotics may not be the same as those observed in patients with *H. pylori* gastritis in an acid-producing stomach. Although the efficacy of these therapy regimens has been thoroughly tested in subjects with *H. pylori* infection, there is a paucity of evidence in the subgroup of patients with AG. Bismuth-based therapy may be an attractive treatment in the specific setting of AG, and specific studies on the efficacy of bismuth-based therapies are needed in patients with AG.

**REFERENCES**

1 **Eusebi LH**, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014; **19** Suppl 1: 1-5 [PMID: 25167938 DOI: 10.1111/hel.12165]

2 **De Francesco V**, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. *Ann Gastroenterol* 2017; **30**: 373-379 [PMID: 28655973 DOI: 10.20524/aog.2017.0166]

3 **Rugge M**, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. *Best Pract Res Clin Gastroenterol* 2013; **27**: 205-223 [PMID: 23809241 DOI: 10.1016/j.bpg.2012.12.007]

4 **Neumann WL**, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 529-541 [PMID: 23774773 DOI: 10.1038/nrgastro.2013.101]

5 **Lahner E**, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. *World J Gastroenterol* 2009; **15**: 5121-8 [PMID 19891010 ]

6 **de Vries AC**, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; **134**: 945-952 [PMID: 18395075 DOI: 10.1053/j.gastro.2008.01.071]

7 **Adamu MA Weck MN**, Gao L, Brenner H. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. *Eur J Epidemiol* 2010; **25**: 439-448 [PMID 20585973 DOI 10.1007/s10654-010-9482-0]

8 Infection with Helicobactor pylori: IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol 61. Schistosomes, Liver Flukes, and Helicobactor pylori. Lyon, International Agency for Research on Cancer, 1994: 177-241

9 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297]

10 **Lee YC**, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology* 2016; **150**: 1113-1124.e5 [PMID: 26836587]

11 **Bae SE**, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations. *Helicobacter* 2018; **23**: e12464 [PMID: 29345408 DOI: 10.1111/hel.12464.]

12 **Rokkas T**, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. *Helicobacter* 2007; **12** Suppl 2: 32-38 [PMID: 17991174 DOI: 10.1111/j.1523-5378.2007.00563.x]

13 **Chen HN**, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. *Gastric Cancer* 2016; **19**: 166-175 [PMID: 25609452 DOI: 10.1007/s10120-015-0462-7]

14 **Vannella L**, Lahner E, Bordi C, Pilozzi E, Di Giulio E, Corleto VD, Osborn J, Delle Fave G, Annibale B. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. *Dig Liver Dis* 2011; **43**: 295-299 [PMID: 21112822 DOI: 10.1016/j.dld.2010.10.012]

15 **Correa P**. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992; **52**: 6735-6740 [PMID: 1458460]

16 **Meining A**, Morgner A, Miehlke S, Bayerdörffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? *Best Pract Res Clin Gastroenterol* 2001; **15**: 983-998 [PMID: 11866488 DOI: 10.1053/bega.2001.0253]

17 **Dias-Jácome E**, Libânio D, Borges-Canha M, Galaghar A, Pimentel-Nunes P. Gastric microbiota and carcinogenesis: the role of non-Helicobacter pylori bacteria - A systematic review. *Rev Esp Enferm Dig* 2016; **108**: 530-540 [PMID: 27604361]

18 **Castaño-Rodríguez N**, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. *Sci Rep* 2017; **7**: 15957 [PMID: 29162924 DOI: 10.1038/s41598-017-16289-2]

19 **Lam SY**, Yu J, Wong SH, Peppelenbosch MP, Fuhler GM. The gastrointestinal microbiota and its role in oncogenesis. *Best Pract Res Clin Gastroenterol* 2017; **31**: 607-618 [PMID: 29566903 DOI: 10.1016/j.bpg.2017.09.010]

20 **Capurso G**, Lahner E. The interaction between smoking, alcohol and the gut microbiome. *Best Pract Res Clin Gastroenterol* 2017; **31**: 579-588 [PMID: 29195678 DOI: 10.1016/j.bpg.2017.10.006]

21 **Dinis-Ribeiro M**, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. *J Clin Pathol* 2004; **57**: 177-182 [PMID: 14747445 DOI: 10.1136/jcp.2003.11270]

22 **Vannella L**, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, Annibale B. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. *Aliment Pharmacol Ther* 2010; **31**: 1042-1050 [PMID: 20175768]

23 **Vannella L**, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. *Aliment Pharmacol Ther* 2013; **37**: 375-382 [PMID: 23216458 DOI: 10.1111/apt.12177]

24 **Spence AD**, Cardwell CR, McMenamin ÚC, Hicks BM, Johnston BT, Murray LJ, Coleman HG. Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review. *BMC Gastroenterol* 2017; **17**: 157 [PMID: 29228909 DOI: 10.1186/s12876-017-0708-4]

25 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

26 **Sugano K**, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* 2015; **64**: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]

27 **Park YH**, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. *J Cancer Prev* 2015; **20**: 25-40 [PMID: 25853101 DOI: 10.15430/JCP.2015.20.1.25]

28 **Annibale B**, Negrini R, Caruana P, Lahner E, Grossi C, Bordi C, Delle Fave G. Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. *Helicobacter* 2001; **6**: 225-233 [PMID: 11683925 DOI: 10.1046/j.1083-4389.2001.00032.x]

29 **Annibale B**, Lahner E, Santucci A, Vaira D, Pasquali A, Severi C, Mini R, Figura N, Delle Fave G. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. *Helicobacter* 2007; **12**: 23-30 [PMID: 17241297 DOI: 10.1111/j.1523-5378.2007.00467.x]

30 **Lahner E**, Vaira D, Figura N, Pilozzi E, Pasquali A, Severi C, Perna F, Delle Fave G, Annibale B. Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. *Helicobacter* 2004; **9**: 436-442 [PMID: 15361083 DOI: 10.1111/j.1083-4389.2004.00262.x]

31 **Atherton JC**, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. *J Clin Invest* 2009; **119**: 2475-2487 [PMID: 19729845 DOI: 10.1172/JCI38605]

32 **Pormohammad A**, Ghotaslou R, Leylabadlo HE, Nasiri MJ, Dabiri H, Hashemi A. Risk of gastric cancer in association with Helicobacter pylori different virulence factors: A systematic review and meta-analysis. *Microb Pathog* 2018; **118**: 214-219 [PMID: 29510208 DOI: 10.1016/j.micpath.2018.03.004]

33 **Lahner E**, Bernardini G, Possenti S, Renzone G, Scaloni A, Santucci A, Annibale B. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. *Int J Med Microbiol* 2011; **301**: 125-132 [PMID: 20843738 DOI: 10.1016/j.ijmm.2010.06.006]

34 **Díaz P**, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression. *Front Microbiol* 2018; **9**: 5 [PMID: 29403459 DOI: 10.3389/fmicb.2018.00005]

35 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

36 **Chey WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 2017; **112**: 212-239 [PMID: 28071659 DOI: 10.1038/ajg.2016.563]

37 **Ushijima T**, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. *Clin Cancer Res* 2012; **18**: 923-929 [PMID: 22205689 DOI: 10.1158/1078-0432.CCR-11-2011]

38 **Zabaleta J**. MicroRNA: A Bridge from H. pylori Infection to Gastritis and Gastric Cancer Development. *Front Genet* 2012; **3**: 294 [PMID: 23248648 DOI: 10.3389/fgene.2012.00294]

39 **Rugge M**, Genta RM. Staging and grading of chronic gastritis. *Hum Pathol* 2005; **36**: 228-233 [PMID: 15791566 DOI: 10.1016/j.humpath.2004.12.008]

40 **Rugge M**, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. *Dig Liver Dis* 2008; **40**: 650-658 [PMID: 18424244 DOI: 10.1016/j.dld.2008.02.030]

41 **Kimura K**, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. *Scand J Gastroenterol Suppl* 1996; **214**: 17-20; discussion 21-3 [PMID: 8722400 DOI: 10.3109/00365529609094509]

42 **Wang J**, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. *Digestion* 2011; **83**: 253-260 [PMID: 21282951 DOI: 10.1159/000280318]

43 **Hwang YJ**, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. *Aliment Pharmacol Ther* 2018; **47**: 380-390 [PMID: 29193217 DOI: 10.1111/apt.14424]

44 **Zagari RM**, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, Farinati F, Ierardi E, Maconi G, Rugge M, Calabrese C, Di Mario F, Luzza F, Pretolani S, Savio A, Gasbarrini G, Caselli M. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. *Dig Liver Dis* 2015; **47**: 903-912 [PMID: 26253555 DOI: 10.1016/j.dld.2015.06.010]

45 National Institute for Health and Care Excellence (NICE) guidelines: Gastro-eesophageal reflux disease and dyspepsia: investigation and management (CG184). NICE 2014: 1-41 Available from: URL: www.nice.org.uk/guidance/cg184/resources/gastrooesophageal-reflux-disease-and-dyspepsia-inadults-investigation-and-management-pdf-35109812699845

46 **Gisbert JP**, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. *Gastroenterol Hepatol* 2016; **39**: 697-721 [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003]

47 **Fallone CA**, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. *Gastroenterology* 2016; **151**: 51-69.e14 [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006]

48 **Liu WZ**, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, Zhou LY, Chen Y, Zeng ZR, Wang CW, Xiao SD, Pan GZ, Hu PJ. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. *J Dig Dis* 2013; **14**: 211-221 [PMID: 23302262 DOI: 10.1111/1751-2980.12034]

49 **Asaka M**, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. *Helicobacter* 2010; **15**: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x.]

50 **Yaxley J**, Chakravarty B. Helicobacter pylori eradication – an update on the latest therapies. *Aust Fam Physician* 2014; **43**: 301-305 [PMID 24791773]

51 **Fock KM**, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; **24**: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x.]

52 **Gatta L**, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; **347**: f4587 [PMID: 23926315 DOI: 10.1136/bmj.f4587]

53 **Yeo YH**, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. *Gut* 2018; **67**: 20-27 [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868]

54 **Xin Y**, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. *BMC Gastroenterol* 2016; **16**: 80 [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7]

55 **Sánchez Cuén JA**, Irineo Cabrales AB, Bernal Magaña G, Peraza Garay F. Regression of gastric intestinal metaplasia after the eradication of Helicobacter pylori infection in a hospital in Mexico. *Rev Esp Enferm Dig* 2016; **108**: 770-775 [PMID: 27804306 DOI: 10.17235/reed.2016.4194/2016]

56 **Kamada T**, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M, Tanaka S, Yoshihara M. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. *Aliment Pharmacol Ther* 2003; **18**: 245-252 [PMID: 12869086 DOI: 10.1046/j.1365-2036.2003.01669.x]

57 **Ohkusa T**, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. *Ann Intern Med* 2001; **134**: 380-6. [DOI: 10.7326/0003-4819-134-5-200103060-00010]

58 **Tillman LA**, Drake FM, Dixon JS, Wood JR. Review article: safety of bismuth in the treatment of gastrointestinal diseases. *Aliment Pharmacol Ther* 1996; **10**: 459-467 [PMID: 8853750 DOI: 10.1046/j.1365-2036.1996.22163000.x]

59 **Wolle K**, Malfertheiner P. Treatment of Helicobacter pylori. *Best Pract Res Clin Gastroenterol* 2007; **21**: 315-324 [PMID: 17382279 DOI: 10.1016/j.bpg.2006.11.001]

60 **de Boer WA**, Driessen WM, Jansz AR, Tytgat GN. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. *Eur J Gastroenterol Hepatol* 1995; **7**: 1189-1194 [PMID: 8789310 DOI: 10.1097/00042737-199512000-00011]

61 **Borody TJ**, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. *Gut* 1995; **37**: 477-481 [PMID: 7489931 DOI: 10.1136/gut.37.4.477]

62 **Malfertheiner P**, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Jaup B, Misiewicz JJ, Pajares J, Quina M, Rauws E. Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). *Eur J Gastroenterol Hepatol* 1997; **9**: 1-2 [PMID: 9031888 DOI: 10.1097/00042737-199701000-00002]

63 **Saleem A**, Qasim A, O'Connor HJ, O'Morain CA. Pylera for the eradication of Helicobacter pylori infection. *Expert Rev Anti Infect Ther* 2009; **7**: 793-799 [PMID: 19735221 DOI: 10.1586/eri.09.55]

64 **Ford AC**, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. *World J Gastroenterol* 2008; **14**: 7361-7370 [PMID: 19109870 DOI: 10.3748/wjg.14.7361]

65 **Fiorini G**, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. *Eur J Gastroenterol Hepatol* 2018; **30**: 621-625 [PMID: 29481383 DOI: 10.1097/MEG.0000000000001102]

66 **Taguchi H**, Kanmura S, Maeda T, Iwaya H, Arima S, Sasaki F, Nasu Y, Tanoue S, Hashimoto S, Ido A. Helicobacter pylori eradication improves the quality of life regardless of the treatment outcome: A multicenter prospective cohort study. *Medicine* (Baltimore) 2017; **96**: e9507 [PMID: 29384953 DOI: 10.1097/MD.0000000000009507]

**P-Reviewer:** Dinç T, SavarinoV, Une C **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Eradication rates reported in previous studies in patients with corporal atrophic gastritis *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Countries** | **Patients, *n*** | **Treatment regimen** | **Cured patients** |
| Sánchez Cuén *et al*[55], 2016 | Mexico | 57 | Omeprazole (40 mg), amoxicillin (1 g), and clarithromycin (500 mg), twice daily for two wk | 49 (85.9) |
| Vannella *et al*[14], 2011 | Italy | 192 | Dicitrate bismuthate (120 mg qds) for 4 wk, plus amoxicillin (1 g tds), and  metronidazole (250 mg tds) during the first 2 wk | 136 (70.8) |
| Kamada *et al*[56], 2003 | Japan | 45 | Omeprazole (20 mg), amoxicillin (1500 mg) and clarithromycin (600 mg) for 1 wk | 35 (82.2) |
| Ohkusa *et al*[57], 2001 | Japan | 163 | Proton-pump inhibitor and antibiotic therapy for 1 wk | 115 (70.5) |



**Figure 1 *Helicobacter pylori* infection, atrophic gastritis and gastric cancer are mutually linked conditions whose natural history may be changed by successful and timely eradication of the organism.** Long-standing *Helicobacter pylori* infection has serious negative effects on the gastric mucosa due to chronic mucosal inflammation leading to alterations in gastric function, such as impaired gastric secretion. These alterations create an intragastric environment that leads to dysbiosis of the gastric microbiota. The end result may be serious histological changes and genetic instability of the gastric mucosa, which in some cases may result in dysplasia and gastric cancer. The timely cure of infection may resolve inflammation, restore gastric functions and normalize the gastric microenvironment, potentially reversing histological damage as well as reducing or preventing the risk of gastric cancer.